Jonathan Trager
Dermatology · Great Neck, NYNPI 1093783367
Payments from drug & device makers
Across 178 payments — averaging $51.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Verrica Pharmaceuticals Inc.$4K
- Incyte Corporation$1K
- Lilly USA, LLC$725
- AbbVie$474
- Pfizer$377
- LEO Pharma Inc.$362
- plus $2K from 17 others
What the payments were for
- Speaking & faculty fees$3,50039%
- Travel & lodging$240%
- Food & beverage$5,47260%
- Education$851%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Verrica Pharmaceuticals Inc. | 5 | $3,672 |
| Incyte Corporation | 34 | $1,033 |
| Lilly USA, LLC | 22 | $725 |
| AbbVie(2 entities) | 16 | $474 |
| Pfizer | 15 | $377 |
| LEO Pharma Inc. | 14 | $362 |
| Sanofi | 8 | $308 |
| Novartis | 15 | $304 |
| E.r. Squibb & Sons, L.L.C. | 9 | $297 |
| UCB, Inc. | 4 | $250 |
| Dermavant Sciences, Inc. | 6 | $237 |
| Galderma Laboratories, L.p. | 3 | $227 |
| Regeneron Healthcare Solutions, Inc. | 7 | $226 |
| Barco, Inc. | 1 | $164 |
| Amgen | 4 | $121 |
| Sun Pharmaceutical Industries Inc. | 5 | $97 |
| Arcutis Biotherapeutics, Inc. | 3 | $61 |
| Organon | 2 | $44 |
| Mayne Pharma Commercial LLC | 1 | $25 |
| Boehringer Ingelheim | 1 | $23 |
| GSK | 1 | $22 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $16 |
| Botanix SB Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,081 in reported general payments places this provider in the 70th percentile of 1,151 dermatology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpzeluraRuxolitinib Phosphate | 22 | $52,998 |
| Clobetasol Propionate | 30 | $1,528 |
| Clobetasol EmollientClobetasol Propionate/Emoll | 14 | $1,086 |
| Ketoconazole | 63 | $973 |
| Triamcinolone Acetonide | 49 | $403 |
| Mupirocin | 26 | $257 |
| Hydrocortisone | 33 | $218 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationOpzelura | $1,033 | $52,99822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,151 dermatology providers in New York.
Other dermatology in Great Neck
- Emma GuttmanNew York$35.3M
- Saakshi KhattriNew York$15.4M
- James KruegerNew York$6.3M
- Michael CameronNew York$5.8M
- Mark LebwohlNew York$5.8M
- Andrew AlexisNew York$5.7M
- John TuRochester$5.4M
- Jeffrey WeinbergKew Gardens$4.9M
- Neil SadickNew York$4.2M
- Alice GottliebSomers$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.